[1]刘雨玲 徐日新.匹伐他汀对冠心病患者血糖影响的研究进展[J].心血管病学进展,2020,(7):710-713.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.010]
　LIU Yuling,XU Rixin.Effect of Pivastatin on Blood Glucose in Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(7):710-713.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.010]
点击复制

匹伐他汀对冠心病患者血糖影响的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年7期
页码:
710-713
栏目:
出版日期:
2020-07-25

文章信息/Info

Title:
Effect of Pivastatin on Blood Glucose in Patients with Coronary Heart Disease
作者:
刘雨玲 徐日新
(1.扬州大学医学院,江苏 扬州225002;2.江苏省苏北人民医院心血管内科,江苏 扬州225002)
Author(s):
102;  102); background-color: rgb(255;  255;  255); font-family: Arial;  Verdana;  sans-serif; font-size: 12pt;">LIU Yuling; XU Rixin
(1.School of Medicine, Yangzhou University, Yangzhou 22500 1, Jiangsu, China; 2.Department of Cardiology, Subei People’s Hospital of Jiangsu Province,Yangzhou 225001 ,Jiangsu,China)
关键词:
匹伐他汀; 冠心病; 血糖
Keywords:
Pivastatin;  Coronary heart disease;  Blood glucose
DOI:
10.16806/j.cnki.issn.1004-3934.2020.07.010
摘要:
随着他汀类药物在冠心病预防中地位不断提高，其所带来的不良影响越来越受到关注，有研究指出他汀类药物会影响糖代谢，甚至导致新发糖尿病发病率升高，匹伐他汀作为新一代人工合成的HMG-CoA还原酶抑制剂，自上市以来其疗效和安全性备受关注，其对血糖的影响结论不一，有研究表明其对糖代谢无明显影响，甚至有积极作用，也有研究指出其影响糖代谢，但新发糖尿病发病率相对较低。现针对匹伐他汀对冠心病患者的血糖影响和作用机制进行系统性综述。
Abstract:
As statins continue to play an important role in the prevention of coronary heart disease, the adverse effects of statins have attracted more and more attention. Several studies have shown that statins affect glucose metabolism and even lead to an increase in the rate of new-onset diabetes. As a new generation of synthetic HMG-CoA reductase inhibitors, pivastatin has been paid much attention to its efficacy and safety since its marketing.The results of the study on the effect and mechanism of pivastatin on blood glucose are different, and there is no uniform conclusion.Some studies have shown that it has no obvious effect on sugar metabolism, even positive effect. Some studies have also pointed out that it affects sugar metabolism, but the rate of new-onset diabetes is relatively low . The effect and mechanism of pivastatin on blood glucose in patients with coronary heart disease were systematically reviewed in this article .

参考文献/References:

[1]国家卫生计生委合理用药专家委员会,中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版) [J]．中国医学前沿杂志(电子版) ,2019,11(1):40-65.

[2]Waters DD. Exploring new indications for statins beyond atherosclerosis:successes and setbacks[J]. J Cardiol,2010,55(2):155-162.

[3]郭若一，郭艺芳．糖尿病患者心血管合并症的防治——解析2018年美国糖尿病协会糖尿病诊疗标准[J]．心血管病学进展,2018,39(2):157-159.

[4]Cui JY, Zhou RR, Han S, et al. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis[J]. J Clin Pharmacy Ther,2018,43(4):556-570.

[5]Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J]. Lancet,2010,375(9716):735-742.

[6]Jinkwon K,Hye SL,Kyung-Yul L. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea[J]. Cardiovasc Diabetol, 2018,17(1):155.

[7]Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus[J]. Am J Cardiol,2013,111(8):1123-1130.

[8]Noji Y,Toshinori H,Inazu A,et al. Long-term treatment with pitavastatin(NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia[J]. Atherosclerosis, 2002,163(1):157-164.

[9]赵水平. 匹伐他汀的临床应用——来自东亚人群的疗效和安全性证据[J].中华内科杂志,2018,57(5):374-377.

[10]Teramoto T,Shimano H,Yokote K,et al. New evidence on pitavastatin:efficacy and safety in clinical studies[J]. Expert Opin Pharmacother,2010,11(5):817-828.

[11]Ahmad H, Cheng-Lai A. Pitavastatin:a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia[J]. Cardiol Rev,2018,18(5):264-267.

[12]Thakker D, Sunita N, Amit P, et al. Statin use and the risk of developing diabetes:a network meta-analysis[J]. Pharmacoepidemiol Drug Safety,2016,25(10):1131-1149.

[13]Swerdlow DI, Sattar N. A dysglycaemic effect of statins in diabetes:relevance to clinical practice? [J]. Diabetologia ,2014,57(12):2433-2435.

[14]Anyanwagu U,Mamza J,Donnelly R,et al. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in following initiation of insulin therapy in type 2 diabetes:a large UK cohort study[J]. Cardiovasc Diabetol,2017,16:107.

[15]吴青青,方译,徐蔓,等.匹伐他汀与阿托伐他汀对血糖影响的Meta分析[J]. 医学研究杂志,2013,42(11):114-117.

[16]田静,李影,刘芳. 匹伐他汀对2型糖尿病模型大鼠肾脏损伤的保护机制[J]. 西北药学杂志,2019,34(1):68-71.

[17]Barrios V, Escobar C. Clinical benefits of pitavastatin:focus on patients with diabetes or at risk of developing diabetes[J]. Future Cardiol,2016,12(4):449-466.

[18]Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes:a meta-analysis of randomized controlled clinical trials in individuals without diabetes[J]. Atherosclerosis,2015,241(2):409-418.

[19]Huang CH, Huang Y Y, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes[J]. J Diabetes Investig,2016,7(5):769-776.

[20]刘思宁,田学峰,王政,等. 不同品种他汀类药物对非糖尿病冠状动脉粥样硬化性心脏病患者糖代谢的影响[J]．中国医药,2019,14(2):192-195.

[21]Choi JY, Choi CU, Hwang SY,et al. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction[J]. Am J Cardiol,2018,122(6):922-928.

[22]Young JH, Jeong MH, Jang HB, et al. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) Ⅱ[J]. Korean J Intern Med,2017,32(4):656-667.

[23]Jeong HS,Hong SJ,Son S,et al. Incidence of new-onset diabetes with 1?mg versus 4?mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up[J]. Cardiovasc Diabetol,2019,18(1):162.

[24]Kim TM, Kim H, Jeong YJ, et al. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients[J]. Pharmacoepidemiol Drug Safety, 2017,26(10):1156-1163.

[25]Millán Nú?ez-Cortés J, Cases Amenós A, Ascaso Gimilio JF,et al. Consensus on the statin of choice in patients with impaired glucose metabolism:results of the Diana study[J]. Am J Cardiovasc Drugs,2017,17(2):135-142.

[26]Brault M,Ray J,Gomez YH,et al. Statin treatment and new-onset diabetes:a review of proposed mechanisms[J]. Metabolism,2014,63(6):735-745.

[27]Swerdlow DI,Preiss D,Kuchenbaecker KB,et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight:evidence from genetic analysis and randomised trials[J]. Lancet (London, England),2015,385(9965):351-361.

[28]Parhoferk G.Interaction between glucose and lipid metabolism:more than diabetic dyslipidemia[J].Diabetes Metab J,2015,39(5):353-362.

[29]Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4):implications in glycaemic control[J]. Diabetologia,2006,49(8):1881-1892.

[30]Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice[J]. Atherosclerosis,2010,212(1):131-138.

[31]Matsubara T, Naruse K, Arakawa T, et al. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: The PREMIUM Study[J]. J Cardiol,2012,60(5):389-394.

[32]Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases[J]. Cell Metab,2013,17(2):185-196.

[33]黄雪莲,黄运英,任竹潇,等. 匹伐他汀通过影响脂肪ClC-3氯通道介导其降脂作用和改善胰岛素抵抗[J]. 中国医师杂志,2014,16(10):1309-1314.

相似文献/References:

[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
　DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
　NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
　LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(7):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
　YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
　SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
　GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(7):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
　DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(7):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
　CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(7):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
　YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
　GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]

更新日期/Last Update: 2020-10-09